It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Large-scale COVID-19 vaccinations are currently underway in many countries in response to the COVID-19 pandemic. Here, we report, besides generation of neutralizing antibodies, consistent alterations in hemoglobin A1c, serum sodium and potassium levels, coagulation profiles, and renal functions in healthy volunteers after vaccination with an inactivated SARS-CoV-2 vaccine. Similar changes had also been reported in COVID-19 patients, suggesting that vaccination mimicked an infection. Single-cell mRNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) before and 28 days after the first inoculation also revealed consistent alterations in gene expression of many different immune cell types. Reduction of CD8+ T cells and increase in classic monocyte contents were exemplary. Moreover, scRNA-seq revealed increased NF-κB signaling and reduced type I interferon responses, which were confirmed by biological assays and also had been reported to occur after SARS-CoV-2 infection with aggravating symptoms. Altogether, our study recommends additional caution when vaccinating people with pre-existing clinical conditions, including diabetes, electrolyte imbalances, renal dysfunction, and coagulation disorders.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Wang Junbang 2 ; Xu Jinfang 3 ; Han, Xia 4
; Wang, Yue 1 ; Zhang Chunxue 1 ; Chen, Wei 1 ; Zhang Huina 1 ; Liu, Qi 1 ; Zhu, Rong 1 ; Shi Yiqi 1 ; Shen Zihao 1 ; Xing Zhonggang 1 ; Gao Wenxia 1 ; Zhou, Liqiang 1
; Shao Jinliang 1 ; Shi Jiayu 1 ; Yang, Xuejiao 1 ; Deng Yaxuan 1 ; Wu, Li 1 ; Lin, Quan 1 ; Zheng Changhong 1 ; Zhu Wenmin 1 ; Wang, Congrong 5 ; Sun, Yi E 1 ; Liu, Zhongmin 1 1 Tongji University, Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai East Hospital, School of Medicine, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535)
2 Tongji University, Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Orthopedic Department of Tongji Hospital, School of Medicine, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535)
3 Second Military Medical University, Department of Health Statistics, Shanghai, China (GRID:grid.73113.37) (ISNI:0000 0004 0369 1660)
4 Chinese Academy of Sciences, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Wuhan, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
5 Tongji University, Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai East Hospital, School of Medicine, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535); Tongji University, Department Endocrinology & Metabolism, Shanghai Fourth People’s Hospital, School of Medicine, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535)




